Antifungal susceptibility testing of micafungin against Candida glabrata isolates

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 105, Issue 4, 2008, Pages 457-459

  Oliveira, Erica R ^a   Fothergill, Annette ^b   Kirkpatrick, William R ^a   Patterson, Thomas F ^a   Redding, Spencer W ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b University of Texas Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ECHINOCANDIN; FLUCONAZOLE; LIPOPROTEIN; MICAFUNGIN;

ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA GLABRATA; DRUG EFFECT; HEAD AND NECK TUMOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; STATISTICS;

ANTIFUNGAL AGENTS; CANDIDA GLABRATA; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FLUCONAZOLE; HEAD AND NECK NEOPLASMS; HIV INFECTIONS; HUMANS; LIPOPROTEINS; MICROBIAL SENSITIVITY TESTS;

EID: 40549087284     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2007.12.003     Document Type: Article

References (16)

1. Colombo A.L., Perfect J., DiNubile M., Bartizal K., Motyl M., Hicks P., et al. Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis. Eur J Clin Microbiol Infect Dis 22 (2003) 470-474
2. Gudlaugsson O., Gillespie S., Lee K., Vande Berg J., Hu J., Messer S., et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37 (2003) 1172-1177
3. Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J., et al. Guidelines for treatment of candidiasis. Clin Infect Dis 38 (2003) 161-189
4. Pfaller M.A., Jones R.N., Doern G.V., Sader H.S., Messer S.A., Houston A., et al. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 44 (2000) 747-751
5. Marr K.A., Seidel K., White T.C., and Bowden R.A. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 181 (2000) 309-316
6. Nguyen M.H., Peacock J.E., Morris A.J., Tanner D.C., Nguyen M.L., Snydman D.R., et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 100 (1996) 617-623
7. Richardson M.D. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 56 (2005) 5-11
8. Denning D.W. Echinocandin antifungal drugs. Lancet 362 (2003) 1142-1151
9. Carver P.L. New drug developments: Micafungin. Ann Pharmacother 38 (2004) 1707-1721
10. Betts R., Rotstein C., Talwar D., Nucci M., De Waele J., Arnold L., et al. Comparison of micafungin and caspofungin for candidemia or invasive candidiasis (2006) Abstract. Annals of the 46th Intercience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, September 27-30.
11. Ostrosky-Zeichner L., Rex J.H., Pappas P.G., Hamill R.J., Larsen R.A., Horowitz H.W., et al. Antifungal susceptibility survey of 2,000 blood-stream Candida isolates in the United States. Antimicrob Agents Chemother 47 (2003) 3149-3154
12. Tawara S., Ikeda F., Maki K., Morishita Y., Otomo K., Teratani N., et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 44 (2000) 57-62
13. Mikamo H., Sato Y., and Tamaya T. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide. J Antimicrob Chemother 46 (2000) 485-487
14. Chavez M., Bernal S., Valverde A., Gutierrez M.J., Quindos G., and Mazuelos E.M. In vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. Isolates from HIV-infected patients. J Antimicrob Chemother 44 (1999) 697-700
15. Ernst E.J., Roling E.E., Petzold C.R., Keele D.J., and Klepser M.E. Ivitro activity of micafungin (FK-463) against Candida spp.: microdilution, time kill, and post-antifungal effect studies. Antimicrob Agents Chemother 46 (2002) 3846-3853
16. Laverdiere M., Hoban D., Restieri C., and Habel F. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother 50 (2002) 119-123